No of isolate
|
Age (month)
|
CHL
|
NA
|
AMP
|
TET
|
KAN
|
CTX
|
CAZ
|
STR
|
STX
|
CIP
|
GEN
|
IMP
|
MEN
|
MDR
|
blaNDM
|
blaSIM
|
blaSPM-1
|
blaGIM
|
blaIMP-1
|
blaIMP-2
|
blaVIM-1
|
blaVIM-2
|
blaKPC
|
oxa-23
|
oxa-48
|
DDST
|
CDT
|
PBA
|
MHT
|
mCIM
|
eCIM
|
MBL
|
Transconjugation
|
MIC
|
Size of plasmids (kb)
|
---|
260
|
12
|
R
|
R
|
R
|
S
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
R
|
R
|
+
|
+
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
+
|
–
|
–
|
–
|
+
|
+
|
+
|
+
|
6
|
3P > 23
|
271
|
36
|
R
|
S
|
R
|
S
|
S
|
R
|
R
|
S
|
S
|
S
|
S
|
R
|
R
|
+
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
+
|
–
|
–
|
–
|
–
|
+
|
–
|
–
|
+
|
+
|
+
|
+
|
6
|
2P > 23
|
335
|
35
|
S
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
R
|
R
|
+
|
+
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
+
|
–
|
–
|
–
|
+
|
+
|
+
|
+
|
5
|
12, 3P > 23
|
175
|
22
|
S
|
R
|
S
|
R
|
R
|
R
|
S
|
R
|
S
|
I
|
I
|
R
|
R
|
+
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
+
|
–
|
–
|
–
|
6
|
16, 12, 1P > 23
|
176
|
36
|
S
|
R
|
R
|
S
|
S
|
R
|
R
|
R
|
S
|
S
|
S
|
R
|
R
|
+
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
+
|
+
|
+
|
+
|
6
|
16, 12
|
317
|
31
|
S
|
R
|
R
|
R
|
I
|
R
|
R
|
R
|
R
|
R
|
S
|
R
|
R
|
+
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
+
|
–
|
+
|
–
|
–
|
+
|
6
|
5, 14
|
- CHL Chloramphenicol, NA Nalidixic-acid, AMP Ampicillin, TET Tetracycline, KAN Kanamycin, CTX cefotaxime, CAZ ceftazidime, STR Streptomycin, STX sulfamethoxazole-trimethoprim, CIP ciprofloxacin, GEN Gentamycin, IMP Imipenem, MEN Meropenem, MDR Multi-drug resistance, ESBL Extended-spectrum beta-lactamases, DDST Double disc synergy test, CDT Combined disc test, PBA Phenylboronic acid, MHT Modified Hodge test, mCIM Modified carbapenem inactivation method, eCIM EDTA-CIM, MBL metalo-beta-lactamase, MIC Minimum inhibitory concentration, P plasmid